These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21683049)

  • 1. A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.
    Abraham AJ; Knudsen HK; Roman PM
    J Stud Alcohol Drugs; 2011 Jul; 72(4):669-77. PubMed ID: 21683049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.
    Abraham AJ; Roman PM
    J Stud Alcohol Drugs; 2010 May; 71(3):460-6. PubMed ID: 20409441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
    Williams EC; Matson TE; Harris AHS
    Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the adoption of medications for alcohol dependence.
    Ducharme LJ; Knudsen HK; Roman PM
    J Clin Psychopharmacol; 2006 Dec; 26 Suppl 1():S13-9. PubMed ID: 17114950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
    Harris AH; Kivlahan DR; Bowe T; Humphreys KN
    Psychiatr Serv; 2010 Apr; 61(4):392-8. PubMed ID: 20360279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological interventions for alcohol misuse in correctional settings: A systematic review.
    Slavin-Stewart C; Minhas M; Turna J; Brasch J; Olagunju AT; Chaimowitz G; MacKillop J
    Alcohol Clin Exp Res; 2022 Jan; 46(1):13-24. PubMed ID: 34825363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.
    Litten RZ; Wilford BB; Falk DE; Ryan ML; Fertig JB
    Subst Abus; 2016; 37(2):286-98. PubMed ID: 26928397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
    Roman PM; Abraham AJ; Knudsen HK
    Addict Behav; 2011 Jun; 36(6):584-589. PubMed ID: 21377275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.
    Abraham AJ; Knudsen HK; Rothrauff TC; Roman PM
    J Subst Abuse Treat; 2010 Apr; 38(3):275-83. PubMed ID: 20117908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.
    Heinrich CJ; Cummings GR
    Health Serv Res; 2014 Feb; 49(1):127-52. PubMed ID: 23855719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
    Aletraris L; Bond Edmond M; Roman PM
    J Stud Alcohol Drugs; 2015 Jan; 76(1):143-51. PubMed ID: 25486403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
    Kranzler HR; Soyka M
    JAMA; 2018 Aug; 320(8):815-824. PubMed ID: 30167705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of healthcare utilization among patients treated with alcoholism medications.
    Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
    Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
    Baser O; Chalk M; Rawson R; Gastfriend DR
    Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
    Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicians' opinions about medications to treat alcoholism.
    Mark TL; Kranzler HR; Song X; Bransberger P; Poole VH; Crosse S
    Addiction; 2003 May; 98(5):617-26. PubMed ID: 12751979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
    Buri C; Moggi F; Giovanoli A; Strik W
    Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of Alcohol Use Disorder.
    Kranzler HR
    Am J Psychiatry; 2023 Aug; 180(8):565-572. PubMed ID: 37525595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone and disulfiram in patients with alcohol dependence and current depression.
    Petrakis I; Ralevski E; Nich C; Levinson C; Carroll K; Poling J; Rounsaville B;
    J Clin Psychopharmacol; 2007 Apr; 27(2):160-5. PubMed ID: 17414239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Pharmacotherapy Development: Human Clinical Studies.
    Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
    Handb Exp Pharmacol; 2018; 248():579-613. PubMed ID: 29294197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.